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Choosing estimands in clinical trials with
missing data
Craig Mallinckrodt,a*Geert Molenberghs,b,c and Suchitrita Rathmanna
Recent research has fostered new guidance on preventing and treating missing data. Consensus exists that clear objectives
should be defined alongwith the causal estimands; trial design and conduct shouldmaximize adherence to the protocol spec-
ified interventions; and a sensible primary analysis should be used along with plausible sensitivity analyses. Two general
categories of estimands are effects of the drug as actually taken (de facto, effectiveness) and effects of the drug if taken as
directed (de jure, efficacy). Motivated by examples, we argue that no single estimand is likely to meet the needs of all stake-
holders and that each estimandhas strengths and limitations. Therefore, stakeholder input shouldbepart of an iterative study
development process that includes choosing estimands that are consistent with trial objectives. To this end, an example is
used to illustrate the benefit from assessingmultiple estimands in the same study. A second example illustrates thatmaximiz-
ing adherence reduces sensitivity tomissing data assumptions for de jure estimands butmay reduce generalizability of results
for de facto estimands if efforts to maximize adherence in the trial are not feasible in clinical practice. A third example illus-
trates thatwhether or not data after initiation of rescuemedication should be included in the primary analysis depends on the
estimand to be tested and the clinical setting. We further discuss the sample size and total exposure to placebo implications
of including post-rescue data in the primary analysis. Copyright © 2016 JohnWiley & Sons, Ltd.
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1. INTRODUCTION
Missing data are an incessant problem in clinical trials that can
bias treatment group comparisons and inflate rates of false neg-
ative and false positive results [1–8]. Fortunately, missing data
have been an active area of investigation with many advances
in statistical theory and in our ability to implement that the-
ory [1,3,5,7,8]. This research set the stage for new and updated
guidance for preventing and handling missing data in clinical tri-
als. Most notably, an expert panel from the National Research
Council (NRC) that was commissioned by FDA issued an extensive
set of recommendations [3].
The NRC recommendations set forth an overarching frame-
work for tackling the problem of missing data. Key pillars of
that framework are (1) clear specification of trial objectives and
causal estimands; (2) trial design and conduct tomaximize adher-
ence to protocol-defined interventions; (3) and a sensible primary
analysis supported by plausible sensitivity analyses that assess
robustness of results to assumptions about the missing data.
The need for clarity in estimands is driven by ambiguities that
can arise from missing data. Data may be intermittently miss-
ing or missing because of dropout. Patients may or may not be
given rescuemedications. Assessments after withdrawal from the
initially randomized medication, or after the addition of rescue
medications, may or may not be taken. If these assessments are
taken, they may or may not be included in analyses [9].
Conceptually, an estimand is simply the true population quan-
tity of interest [3]; this is specific to a particular parameter, time
point, and population. Given the emphasis on clear objectives,
the choice of the primary estimand has been the subject of con-
siderable discussion [1,3,4,8–17]. With the variety of clinical trial
scenarios and missing data possibilities, consensus on a univer-
sally best estimand is neither realistic nor desirable. Therefore,
attention has shifted to how to choose estimands.
For clarity, the following distinction is made. Patient dropout
occurs when the patient discontinues the initially randomized
study medication and no further observations are taken. Analysis
dropout occurs when patients deviate from the originally ran-
domized treatment regime (stops medication and/or adds rescue
medication) and observations are taken but they are not included
in the analysis because they are not relevant for the estimand
being evaluated.
Leuchs et al. [11] proposed a process chart that begins with
defining the primary estimand, followed by determining design,
analysis, and sensitivity analyses. In a letter to the editor in
response to the Leuchs et al. paper, the PSI/EPSI working group
(WG) on estimands advocated an additional step prior to choos-
ing the primary estimand. TheWGproposal began by considering
objectives and then proceeded to the other steps in an iterative
manner so that interactions between the various components
could be considered [12]. The WG expanded on these ideas in a
subsequent paper [17].
The purpose of the present paper is to utilize this iterative
study development process to illustrate key issues in choosing
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estimands. The paper is organized by providing an overview of
objectives and estimands in Section 2. Fundamental considera-
tions for estimands are discussed along with considerations for
use of rescue data, trial design, and analysis in Section 3. These
considerations are illustrated via examples in Section 4. The dis-
cussion in Section 5 ties these ideas together.
2. OBJECTIVES AND ESTIMANDS
Trial objectives are typically driven by the decisions to be made
from the trial results. These decisions depend in part on stage of
development. Phase II trials are typically used by drug developers
to determine proof of concept or to choose doses for subse-
quent studies. Confirmatory (phase 3) studies typically serve a
diverse audience and address diverse objectives [11]. For exam-
ple, regulators render decisions regarding whether or not the
drug under study should be granted a marketing authorization.
Drug developers and regulators must collaborate to develop
labeling language that accurately and clearly describes the risks
and benefits of approved drugs. Payers must decide if/where a
newdrug belongs on its formulary list. Prescribersmust decide if a
drug should be prescribed to particular patients and must inform
those patients and/or their caregivers of what to expect. Patients
and caregivers must decide if they want to take the drug that has
been prescribed.
Clearly defined objectives and estimands lead to clarity in
appropriate analyses. It is useful to start by considering the two
well-known categories of estimands: efficacy and effectiveness.
Efficacy may be viewed as the effects of the drug if taken as
directed, with effectiveness being the effects of the drug as actu-
ally taken [1,6,10,11,14,15]. However, this nomenclature does not
make sense for safety outcomes. Therefore, the more general ter-
minology of de jure (if taken as directed) and de facto (as actually
taken) can be useful [13].
The NRC guidance [3] discusses five estimands in detail, and
Mallinckrodt et al. [10] proposed a sixth estimand. The focus here
is on three of those estimands to illustrate many of the considera-
tions in choosing estimands. Each of the three estimands involves
the difference versus control in changes to the planned endpoint
of the trial, in all randomized patients.
1. Estimand 1 is the change due to the treatment regimens as
actually taken.
2. Estimand 2 is the change due to the initially randomized
treatments as actually taken.
3. Estimand 3 is the change due to the initially randomized
treatments if taken as directed.
The distinction between estimands 1 and 2 is whether or not
data after discontinuation of the initially randomized treatment
and/or initiation of rescue treatment are needed to estimate the
estimand. Post-discontinuation and post-rescue data are needed
for estimand 1 but are not needed for estimand 2.
It is also important to differentiate estimand 3, which is based
on all randomized patients, from what is estimated in a com-
pleters analysis. In a completers analysis, the estimand is condi-
tional on having been adherent. In addition, completers analyses
do not preserve the initial randomization. In contrast, estimand
3 includes all randomized patients. Therefore, in principle, infer-
ences and parameter estimates from estimand 3 apply to all
patients in the population, not merely to those who were doing
well enough to remain adherent.
Another potential de jure estimand not discussed in detail here
is the de jure estimand in patients who were shown to toler-
ate the experimental drug during a run-in phase. This estimand
was discussed in the NRC guidance [3]. The intent of this ‘tol-
erator’ estimand is similar to that of estimand 3. However, the
tolerator estimand draws inference regarding drug benefit from
the subset of patients that tolerated the drug during the run-in
phase and were subsequently randomized. Safety assessments
would have to come from all patients exposed to the experimen-
tal drug. Therefore, when this design is used, inference for safety
and efficacy are not drawn from the same group of patients.
Table I relates the numbering of the three focus estimands in
this paper to the numbering used in the NRC guidance [3] and in
Mallinckrodt et al. [10].
3. CONSIDERATIONS
3.1. Fundamental considerations
Given the diversity in clinical settings and in the decisions to be
made from clinical trial data, no universally best primary estimand
exists, and multiple estimands are likely to be of interest for any
one trial [1,10–12,14,15,17].
The three common estimands defined in Section 2 each have
strengths and limitations. The de jure estimand (estimand 3) can
be considered hypothetical (i.e., counterfactual) for groups of
patients because treatment effects are assessed as if taken as
directed when in any meaningfully sized group, some patients
will not adhere [3]. However, the de jure estimand is relevant
because knowing what to expect when patients adhere is impor-
tant. Patients are advised to take their medication as directed;
therefore, it is important to assess what happens if a medication
is taken as directed so that optimal directions can be developed.
Example 1 in Section 4 illustrates the role that estimand 3 can play
in optimizing drug development and patient care.
De facto estimands can be considered counterfactual for indi-
vidual patients because treatment effects are assessed from amix
of adherent and non-adherent patients, but each patient is either
adherent or not adherent, no patient is both. On the other hand,
de facto estimands can provide useful estimates of what to expect
from the group as a whole [2,3].
Most of the discussion on de jure and de facto estimands has
been in the context of assessing drug benefit. However, esti-
mands for assessing drug risk are also important. Consider the
following hypothetical example. A drug increases blood pressure.
Some patients become hypertensive and discontinue studymed-
ication and/or take rescue medication, with subsequent return
to normal blood pressure. De facto estimands would reflect the
patients’ return to normal, thereby suggesting no change in
blood pressure at the planned endpoint of the trial. De jure esti-
mands would not reflect a return to normal and would reflect
increases at endpoint because had the patients been adherent
Table I. Number references of estimands in various
publications.
Reference number
This paper NRC guidance Mallinckrodt et al. [10]
1 1 1
2 Estimand not mentioned 6
3 3 3
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they would likely have continued to be hypertensive. Therefore,
for safety assessments, de jure estimands may be particularly
relevant.
Another important fundamental consideration is whether or
not the estimand is consistent with the intention-to-treat (ITT)
principle. The ICH E9 guidance [18] defines ITT as ‘the princi-
ple that asserts that the effect of a treatment policy can be best
assessed by evaluating on the basis of the intention to treat a sub-
ject (i.e. the planned treatment regimen) rather than the actual
treatment given’. The guidance parses ITT into two parts: the
patients to include and the data for each patient to include. The
guidance is clear on the need to include all randomized patients.
The de jure estimand based on completers is clearly not consis-
tent with ITT because it does not include all randomized patients.
In contrast, consider de jure estimand 3 defined in Section 2.
This estimand includes all randomized patients and is therefore
consistent with ITT in that regard. Additional aspects of ITT are
covered in the next section. In contrast to the ICH guidance,
an FDA WG on missing data noted common situations in which
estimands could be adequately addressed by patient subsets [16].
3.2. Rescuemedication considerations
Whether or not data collected after initiation of rescue medi-
cation (or discontinuation of initially randomized study medica-
tion) should be included in the primary analysis is an important
consideration. Rescue medication by definition is intended to
change outcomes. Therefore, effective rescue medication can
mask or exaggerate the efficacy and safety effects of the ini-
tially assigned treatments, thereby biasing estimates of their
effects [1,10,14,15,19–21].
The ICH E9 guidance [18] definition of ITT states ‘that subjects
allocated to a treatment group should be followed up, assessed
and analyzed as members of that group irrespective of their com-
pliance to the planned course of treatment’. Importantly, the E9
guidance refers to ITT in the context of assessing treatment regi-
mens and does not address inference for the initially randomized
medications, such as is the case with estimands 2 and 3.
Rescue therapy is specifically addressed in ICH E10, section
2.1.5.2.2 [22]. In referring to trials with rescue, E10 states: ‘In such
cases, the need to change treatment becomes a study endpoint’.
This approach suggests that at the point of rescue, it is
known that the treatment did not work for that patient and that
post-rescue data need not be included in the primary analysis.
Instead, the primary analysis might include adherence and need
for rescue as part of a composite endpoint or as the sole primary
endpoint. However, the estimand is not explicitly stated in the E10
guidance, and therefore, ambiguity remains about if and when
post-rescue data should be included in the primary analysis. The
ICH guidance was issued prior to the more nuanced discussion of
estimands that is taking place today.
The perceived need for rescue therapy may be partly moti-
vated by arguments for ethical patient care, especially in
placebo-controlled trials. However, in placebo-controlled trials,
if rescue therapy is beneficial, including post-rescue data is
likely to substantially decrease the magnitude of the treatment
effect compared with de jure or de facto estimands that exclude
post-rescue data. Therefore, tomaintain power, an increased sam-
ple size is needed, which exposes more patients to placebo [19].
With estimand 1 (de facto, treatment regimens), data after
discontinuation of the initially randomized medication and/or
addition of rescue medication are included in the analyses [3].
Therefore, inference for estimand 1 is in regard to treatment
regimens [1,7,9–11,14,15]. However, the most relevant questions
in early research and initial regulatory review, especially for
placebo-controlled trials, are often about the effects of the investi-
gational drug, not treatment regimens involving the investigation
drug [1,10,15].
O’Neill and Temple [14] noted that primary estimands requiring
data after withdrawal of randomized medication and/or initia-
tion of rescue may be more common in outcomes trials where
the presence/absence of a major health event is the endpoint
and/or the intervention is intended to modify the disease pro-
cess. Symptomatic trials (symptom severity is the endpoint) typi-
cally focus on inferences regarding the initially randomized treat-
ments. Symptomatic trials can avoid the confounding from res-
cue medications by using a primary estimand and analysis that
exclude data after initiation of rescue/discontinuation of initial
medication.
Conceptually, estimand 2 (de facto, initially randomized treat-
ments) avoids the confounding effects of rescue medications on
inferences regarding the initially randomized treatments by not
allowing rescue medication. However, given the ethical mandate
to allow rescue medications and the analytic need to exclude
post-rescue data, the issue of how to estimate estimand 2 is
covered in Section 3.4.
For estimand 3 (de jure, initially randomized treatments), data
after discontinuation of treatment or initiation of rescue are
not required.
3.3. Design considerations
Universal agreement exists that trials should aim to maximize
adherence to protocol procedures, including adherence to the
initially assigned treatments [1–3,8,14,15]. Maximizing adher-
ence improves robustness of results by reducing the reliance
of inferences on the untestable assumptions about the missing
data [1,3,5,7,8,14,15,23]. These considerations have often been in
the context of de jure estimands. However, the impact of max-
imizing retention on de facto estimands should also be consid-
ered [11].
Increasing adherence is likely to increase benefit from the drug
as actually taken, thereby resulting in more favorable estimates
of de facto estimands. If the measures used to engender adher-
ence in the clinical trial are not feasible in clinical practice, the
trial could yield biased estimates of effectiveness relative to the
conditions under which the drug would be used.
Specifically, assessment of de facto estimands often entails
using adherence as part of the primary outcome. For example,
patients that discontinue study drug are often considered a treat-
ment failure regardless of the observed outcomes. Therefore, it is
important to consider the degree to which treatment adherence
decisions in the clinical trial match adherence decisions in clinical
practice. These generalizability considerations may be especially
important in trials with placebo and/or blinding because these
factors are never present in clinical practice [1].
3.4. Analysis considerations
In the iterative study development process advocated by Leuchs
et al. [11] and the PSI/EPSI WG on estimands [17], it is possible
for analytic considerations to influence choice of estimands. For
example, interest may center on a particular estimand, but if a
robust analysis (and/or design) cannot be paired with this esti-
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mand, it may be better to focus on a related estimand for which a
robust analysis (and/or design) exists. Therefore, it is important to
understand the attributes of analytic approaches when choosing
estimands.
TheNRCpanel [3] suggested that the primary analysis for the de
facto treatment regimen estimand (estimand 1) be based on the
assumption that data aremissing at random. A number of authors
have suggested that a similar assumption be used for estimand
3, the de jure estimand [1,5–9,13–15,23]. This assumption is far
less restrictive than missing completely at random and is at least
a good starting point in clinical trial analyses [1,3,5,7,8,14,15,23].
The plausibility of MAR hinges in part on having minimal loss to
follow-up. When patients are lost to follow-up, data explaining
why they discontinued study medication are not fully available,
making model assumptions more suspect than if such data were
available.
Post-rescue data are included for estimand 1 but not for esti-
mand 3. Therefore, in any particular dataset, fewer observations
will be missing for estimand 1 than for estimand 3. Regardless,
validity of MAR can never be proven, hence the need for plausible
sensitivity analyses [1,14,15,23,24].
One approach to assessing estimand 2 is to impute the data
after initiation of rescue and/or discontinuation of the initially ran-
domized medication under the assumption that initially random-
izedmedications have no (or diminished) effect after discontinua-
tion/rescue [1,7,8,10,13–15]. This assumption is often reasonable
in trials of symptomatic interventions [4,25].
Such imputations for continuous endpoints have historically
been performed using baseline observation carried forward
(BOCF). For categorical endpoints, non-responder imputation
(NRI) has often been used. With NRI, all patients who discontinue
initially randomized medication and/or initiate rescue medica-
tion are considered non-responders, regardless of the observed
outcomes. However, single imputation approaches such as BOCF
and NRI have a number of disadvantages, and more principled
approaches are gaining favor [1,10,13,15,26].
In BOCF and NRI, the assumption of no change from baseline is
made in order to ascribe no pharmacologic benefit from the drug
if it is discontinued. However, these approaches ignore the poten-
tial changes from non-pharmacologic sources that are often seen
in trials (study effect and placebo effect) and would therefore be
valid only in those situations where there was no change in a
placebo group over time [1,10,15].
The bias in BOCF estimates can be large, resulting in inflated
type I error rates or loss of power in testing de facto esti-
mands [27]. In addition, BOCFmakes no sense in situations where
the therapeutic aim is to prevent worsening because carrying
the baseline observation forward ascribes a good outcome to
patients who discontinue [1]. Moreover, as a single imputation
technique, BOCF assigns the same change score (zero) to every
patient who discontinues, which results in underestimates of vari-
ance and standard error. Therefore, BOCF is generally not a useful
analytic approach [1,3,5,7,8,10,15,16,24].
Multiple imputation-based approaches to test de facto esti-
mands have come into the literature recently. These methods
have been referred to as controlled imputation or more specif-
ically reference-based controlled imputation [1,7,8,13–15]. Full
descriptions of these approaches go beyond the present scope.
However, the general idea is to use multiple imputation in a man-
ner that accounts for the change in/discontinuation of treatment.
In so doing, patients who discontinue from an experimental arm
have values imputed as if they were in the reference (e.g., placebo
arm). Depending on the exact implementation, imputed values
can either reflect no pharmacologic benefit from the drug imme-
diately upon discontinuation/rescue, a decaying benefit after
discontinuation/rescue, or a constant benefit after discontinua-
tion/rescue [7,8,13–15].
In contrast to BOCF, reference-based imputation via multiple
imputation accounts for the uncertainty of imputation, accounts
for study/placebo effects, and can therefore be applied regard-
less of whether the therapeutic aim is improvement or preven-
tion of worsening [1,7,8,13,14]. Reference-based imputation has
been shown to reduce bias and provide better control of type 1
error compared with BOCF [28]. Some reference-based imputa-
tionmethods can now be implemented in commercially available
software [27]. Specialty programs have also been made freely
available to the public at www.missingdata.org.uk.
4. EXAMPLES
Three short examples are presented. The first example illustrates
the benefits of assessing both de jure and de facto estimands
in the same trial. The second example illustrates the impact of
increasing adherence on de jure and de facto estimands regarding
the initially randomized treatments. The third example illustrates
the impact of including post-rescue data in analyses.
First, consider the following hypothetical example where effec-
tiveness is a function of efficacy and adherence. Drugs A and
B (or doses A and B of a drug) have equal effectiveness, but A
has significantly greater efficacy and B has significantly greater
adherence.
Efficacy Adherence Effectiveness
Drug A High Low Average
Drug B Low High Average
These differences in clinical profiles have important implica-
tions. Dose/drug A might be the best choice for patients with
more severe illness because it has greater efficacy. Dose/drug B
might be best for patients with less severe illness and/or safety
and tolerability concerns because it has greater adherence result-
ing from fewer side effects. In the context of two doses of a
drug, the more nuanced understanding of efficacy and adher-
ence could lead to additional investigation that fosters better
patient outcomes. For example, subgroups of patients who espe-
cially benefit from or tolerate the high dose might be identified
from the existing data or from a new trial (non-responders to
low dose). Or alternate dosing regimens that might improve the
safety/tolerability of the high dose, such as titration, flexible, or
split dosing (40 mg every 2 weeks rather than 80 mg every
4 weeks), could be investigated in subsequent trials.
Example 2 is from two clinical trials in depression [29,30]. These
trials have been used in a previous examination of sensitivity
analyses [14]. The datasets were somewhat contrived to avoid
implications for marketed products, but key features of the orig-
inal data were preserved. Assessments on the Hamilton 17-item
Rating Scale for Depression [31] were taken at baseline andweeks
1, 2, 4, 6, and 8 in each trial. These trials are referred to as the
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low and high dropout datasets. In the high dropout dataset, com-
pletion rates were 70% for drug and 60% for placebo. In the low
dropout dataset, completion rates were 92% in both arms.
The design differences that may explain the difference in
dropout rates between these two otherwise similar trials were
that the low dropout dataset came from a study conducted in
Eastern Europe that included a 6-month extension treatment
period after the 8-week acute treatment phase and used titration
dosing. The high dropout dataset came from a study conducted
in the USA that did not have the extension treatment period and
used fixed dosing.
Estimates of de facto and de jure estimands regarding the ini-
tially randomized treatments (estimands 2 and 3 in Section 2,
respectively) were obtained from each dataset in order to illus-
trate the impact of higher and lower adherence.
The de facto estimand was assessed by defining each patient
as a treatment success or failure. Treatment success was defined
as improvement 50% of the baseline severity and completion
of the acute treatment phase. Treatment failure was defined as
<50% improvement from baseline or discontinuation of study
medication prior to endpoint. Treatment groups were compared
using Fisher’s exact test. The treatment success/failure approach
results in the same numeric quantity as NRI. However, the result
is interpreted differently. The definition of the treatment success
included dropout, so there were no missing data and no need
to assess sensitivity. In contrast, with NRI, as the name implies,
response status is imputed, and hence, sensitivity would need to
be assessed.
The de jure estimand was estimated using a restricted
maximum likelihood-based repeated measures approach. The
analyses included the fixed, categorical effects of treatment,
investigative site, visit, the continuous, fixed covariate of base-
line score, and all two-way interactions with visit. An unstructured
(co)variance structure shared across treatment groups was used
to model the within-patient errors. The Kenward–Roger approx-
imation was used to estimate denominator degrees of freedom
and adjust standard errors. Analyses were implemented using
SAS PROC MIXED [27]. The primary comparison was the contrast
(difference in LSMEANS) between treatments at week 8.
Sensitivity of the de jure results to departures from MAR was
assessed using the reference-based imputation approach known
as jump to references (J2R) [13,14]. In J2R, values for refer-
ence group are imputed assuming MAR; values for drug-treated
patients are imputed assuming MNAR such that the benefit from
the drug immediately disappearing after discontinuation of study
drug. Therefore, the estimate of the treatment effect from J2R
will be smaller than the corresponding estimate assuming MAR
for both treatment arms. Although J2R can be implemented as
an assessment of estimand 2, it can also be implemented as it is
here, a worst reasonable case departure from MAR. That is, the
same numeric quantity, the estimate from J2R, can be interpreted
as either an assessment of estimand 2 or a sensitivity analysis for
estimand 3.
The J2R imputations in this re-analysis used the placebo group
as the reference group and had a full multivariate repeated
measures model for parameter estimation. That model included
treatment, investigative site, and baseline score, all crossed with
visit. The analysis model was analysis of variance at week 8 with
treatment, baseline, and investigative site in the model.
A full discussion of sensitivity analyses is beyond the present
scope. However, it is important to appreciate that the reference
distribution in J2R is not based solely on completers; instead, MAR
is assumed for the reference arm such that patients with poor
outcomes who drop out early contribute to the reference distri-
bution. However, as in other applications, the assumption of MAR
or any specific MNAR mechanism cannot be validated from the
observed outcomes and/or reasons for discontinuation.
Results from example 2 are summarized in Table II. For both
datasets, the MAR-based analysis of the de jure estimand yielded
a significant treatment contrast. In the low dropout dataset, the
J2R sensitivity analysis yielded a treatment effect very close to the
MAR estimate. However, in the high dropout dataset, the differ-
ence between the MAR and J2R result was fivefold greater than
in the low dropout dataset, and statistical significance was not
preserved. Therefore, with low dropout, inference regarding the
de jure estimand was robust to plausible departure from MAR,
whereas results from the high dropout dataset were not robust to
plausible departure fromMAR.
In regard to the de facto estimand, both trials yielded signif-
icant differences in treatment success. However, generalizabil-
ity must be considered. The low dropout dataset had greater
within-group mean changes and greater adherence. The percent
treatment success on placebo in the low dropout dataset was
twofold greater than in the high dropout dataset. It is not certain
from this example if or how the design differences influenced the
within-groupmean changes and adherence. However, the two tri-
als did give different views of effectiveness, and in a real scenario,
it would be important to justify generalizability of effectiveness
results.
Table II. Results from examle 2.
High dropout Low dropout
LSMEANS LSMEAN LSMEANS LSMEAN
Placebo Drug DifferenceŠ P-value Placebo Drug DifferenceŠ P-value
MAR 5.95 8.24 2.29 (1.00) 0.024 10.56 12.40 1.84 (0.70) 0.009
J2R 5.97 7.57 1.60 (0.99) 0.110 10.55 12.26 1.72 (0.70) 0.016
Treatment success (%) Treatment success (%)
Placebo Drug Difference P-value Placebo Drug Difference P-value
25 39 14 0.034 50 68 18 0.001
ŠLSMEANS are mean change from baseline in Hamilton 17-item Rating Scale for Depression total
score. LSMEAN difference is the contrast between drug and placebo at the planned endpoint
assessment (week 8). Values in parenthesis are the standard errors of the LSMEAN differences.
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Example 3 is from a clinical trial in psoriatic arthritis. For full
details of the study, see NCT01695239 in www.clinicaltrials.gov.
Patients were randomized in a 1:1:1:1 ratio to two doses of an
experimental drug, a known effective standard of care (adali-
mumab, humira) and placebo. This investigation focuses on only
the standard of care and placebo arms. Assessments were taken
at baseline, weeks 1, 2, 4, 8, 12, 16, 20, and 24. After week 16,
patients with inadequate response were allowed to have changes
in background therapy as rescue. As additional rescue therapy,
patients initially randomized to placebo were re-randomized to
one of the two doses of the experimental medication until week
24, the time of the primary assessment. This additional rescue
intervention could not be implemented for the standard of care
arm because of safety concerns related to switching immediately
from one active medication to another.
These data are used to compare results when including ver-
sus not including post-rescue data in the analyses. Specifically,
this re-analysis compared results from estimand 1 (treatment reg-
imens as actually taken) and estimand 2 (initially randomized
treatments as actually taken) with regard to the percentage of
patients meeting ACR20 criteria. This variable is a common choice
for the primary analysis and essentially assesses whether or not
patients had a 20% improvement from baseline in signs and
symptoms of their psoriatic arthritis.
For estimand 1, patients were considered a treatment success if
theymet ACR20 criteria at week 24, and patients were considered
a treatment failure if they did not meet ACR20 criteria at week 24
or they discontinued study medication. For estimand 2, patients
were considered a treatment success if they met ACR20 criteria at
week 24 and did not receive rescue treatment. Patients were con-
sidered a treatment failure if they did not meet ACR20 criteria at
week 24, or they discontinued study medication, or they required
rescue medication.
The difference between the two results reflects the effects of
rescue medication. In the adalimumab arm, 12 of 101 patients
met criteria for rescue treatment and 3 (25%) rescued patients
met ACR20 criteria at week 24. In the placebo arm, 45 of 106
patients met criteria for rescue treatment and 13 (29%) rescued
patients met ACR20 criteria at week 24. Results are summarized in
Table III.
Treatment success rates without post-rescue data showed an
advantage of drug over placebo of approximately 27% versus
an advantage of 18% when post-rescue data were included.
Treatment groups differed significantly (p < 0.01) regardless of
whether or not post-rescue data were included. However, if the
rate of rescue success in the placebo arm had been 17 of 45 (38%)
instead of 13 of 45 (29%), significance would have been lost when
including post-rescue data.
Powering a future study based on results of estimand 2 sug-
gests that 75 patients per arm would yield 90% power, whereas
results from estimand 1 suggest that 175 patients per arm are
needed for 90%power, therebymore than doubling the exposure
to placebo.
5. DISCUSSION
Consensus exists that the best way to deal with missing data is
to prevent it and that a sensible primary analysis should be sup-
ported by appropriate sensitivity analyses. Consensus also exists
on the need for clarity in objectives and estimands. However,
given the diverse settings in which clinical trials are conducted, it
is neither realistic nor desirable to seek consensus on a universally
best primary estimand, primary analysis, or approach to sensi-
tivity analyses. Therefore, discussion is shifting to the process by
which these decisions are made.
Leuchs et al. [11] suggested a process chart that begins with
choice of the primary estimand, after which design, analysis,
and sensitivity analyses are determined. The PSI/EFSPI WG advo-
cated a refinement of that proposal wherein trial objectives drive
choice of estimands in an iterative process to allow design and
analysis considerations to be factored into the choice of esti-
mand(s) [12,17].
The intent of the present paper is not to illustrate specific
choices of estimands for specific situations. Rather, the intent is
to examine considerations for choosing estimands using three
focus estimands. These three are not the only estimands of inter-
est in clinical trials. For example, an estimand noted in the NRC
guidance [3] that was not discussed here is the de jure estimand
in patients who were shown to tolerate the experimental drug
during a run-in phase.
Examples were used to illustrate the benefits of multiple esti-
mands in the same trial, the consequences of increasing adher-
ence, and the consequences of including post-rescue data. In
the iterative process proposed by the WG, design and analy-
sis considerations can influence objectives and estimands. This
is not in conflict with the notion that handling of missing data
should not compromise the meaningfulness of endpoints and
estimands [32]. Rather, jointly considering all aspects of the pro-
cess can lead to objectives, estimands, and designs that are more
relevant given the circumstances.
For example, consider a 6-week acute phase clinical trial for
patients hospitalized with an acute exacerbation of schizophre-
nia. In this highly controlled, inpatient setting, assume that 95%of
patients will adhere to the initially assigned study medication. A
de jure primary estimand is consistent with this highly controlled
setting. With 95% adherence, plausible departures from MAR are
unlikely to overturn positive findings for a de jure estimand. In
Table III. Number and percent of patients meeting treatment suc-
cess criteria with and without inclusion of post-rescue data in
example 3.
Adalimumab Placebo
(n D 101) (n D 106) Difference
Without post-rescue data 58 (57.4%) 32 (30.2%) 27.2 %
(estimand 2)
With post-rescue data 61 (60.4%) 45 (42.5%) 17.9 %
(estimand 1)
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comparison, consider a trial to assess long-term treatment in the
same disease state. The rigid control from the inpatient setting
is too burdensome on patients and can be maintained for only a
short duration. A less restrictive outpatient design is needed after
the initial exacerbation is under control. However, in the outpa-
tient setting, lack of adherence to the initial medication can be a
significant concern. A de factoprimary estimand is consistentwith
the more pragmatic design and goals of the long-term trial and
with the inevitable loss of adherence over the longer treatment
period.
As another example of the interplay between estimands,
design, and analyses, consider example 3 in the previous section.
The primary assessment time was week 24, with rescue first avail-
able at week 16. The more nuanced discussions of estimands that
are present today compared with when the example study was
planned may have led investigators to choose a primary end-
point of week 16 if estimand 2 or estimand 3 was primary, but
week 24 if estimand 1 was primary. If estimand 1 was chosen as
primary, that choice may have influenced choice of comparator.
Estimand 1 is often used as a pragmatic assessment of effec-
tiveness [16]. However, placebo is never used in clinical practice.
Therefore, placebo control may be less consistent with estimand
1 than active control.
As another example of how other factors can influence choice
of estimand, consider a trial where focus is on effectiveness, but
interest is in both estimand 1 and estimand 2; that is, results with
and without post-rescue data are relevant. Also, consider that in
this scenario, it is important to keep the sample size as small as
possible either because patients are hard to recruit or for ethical
reasons, it is important to limit exposure to placebo. Use of esti-
mand 2 as the primary estimand is likely to result in greater power,
which translates into smaller sample sizes and reduced exposure
to placebo. Post-rescue data may still be collected and used in
secondary analyses.
The multifaceted nature of clinical trials is important to con-
sider in choosing estimands [10–12,17]. Objectives early in devel-
opment often differ from objectives later in development. Even
within confirmatory trials, diverse objectives are needed to inform
the decisions regulators, health technology assessors/payers, pre-
scribers, patients, caregivers, sponsors, other researchers, and so
on must make. Even for a single stakeholder in a single trial, it
is often important to know what happens when a drug is taken
as directed (de jure estimand) and to know what happens when
the drug is taken as in actual practice (de facto estimand). There-
fore, no single estimand is likely to best serve the interests of all
stakeholders, and de jure and de facto estimands will both be of
interest [1,10–12,17].
By including de facto and de jure estimands in a single trial,
those who make decisions about individual patients (prescribers,
patients, caregivers, etc.) may focusmost on the de jure estimands
and secondarily on de facto estimands. Thosewhomake decisions
about groups of patients (e.g., regulators) may focus most on de
facto estimands. However, all decision makers will benefit from
understanding results from both de jure and de facto estimands.
6. CONCLUSIONS
An iterative process should be used to choose estimands, begin-
ning with the objectives required to address the needs of diverse
stakeholders. No single estimand is likely to meet the needs
of all stakeholders. De jure and de facto estimands each have
strengths and limitations. Fully understanding a drug’s effects
requires understanding results from both families of estimands.
Maximizing adherence reduces sensitivity to missing data
assumptions for de jure estimands. However, it is also important to
consider generalizability of results for de facto estimands if efforts
to maximize adherence in the trial are not feasible in clinical
practice. Whether or not data after initiation of rescue medica-
tion should be included in the primary analysis depends on the
estimand to be tested and the clinical setting.
REFERENCES
[1] Mallinckrodt CH. Preventing and treating missing data in longitudi-
nal clinical trials: a practical guide. Cambridge University Press: New
York, 2013.
[2] Committee for Medicinal Products for Human Use (CHMP).
Guideline on missing data in confirmatory clinical trials. 2010.
EMA/CPMP/EWP/1776/99 Rev. 1.
[3] National Research Council. The prevention and treatment of miss-
ing data in clinical trials. Panel on handling missing data in clini-
cal trials. Committee on National Statistics, Division of Behavioural
and Social Sciences and Education. The National Academies Press:
Washington, DC, 2010.
[4] O’Neill RT, Temple R. The prevention and treatment of miss-
ing data in clinical trials: an FDA perspective on the importance
of dealing with it. Clinical Pharmacology and Therapeutics. 2012;
91(3):550–554.
[5] Molenberghs G, Kenward MG. Missing data in clinical studies. John
Wiley & Sons: Chichester, 2007.
[6] Mallinckrodt CH, Lane PW, Schnell D, Peng Y, Mancuso JP. Recom-
mendations for the primary analysis of continuous endpoints in lon-
gitudinal clinical trials. Drug Information Journal 2008; 42:305–319.
[7] Molenberghs G, Fitzmaurice G, Kenward M, Tsiatis A, Verbeke G.
Handbook of missing data methodology. CRC Press: Boca Raton,
2015.
[8] O’Kelly M, Ratitch B. Clinical trials with missing data. Wiley:
Chichester, 2014.
[9] Mallinckrodt CH, Kenward MG. Conceptual considerations regard-
ing choice of endpoints, hypotheses, and analyses in longitudinal
clinical trials. Drug Information Journal 2009; 43(4):449–458.
[10] Mallinckrodt CH, Lin Q, Lipkovich I, Molenberghs G. A structured
approach to choosing estimands and estimators in longitudinal
clinical trials. Pharmaceutical Statistics 2012; 11:456–461.
[11] Leuchs AK, Zinserling J, Brandt A, Wirtz D, Benda N. Choosing
appropriate estimands in clinical trials. Therapeutic Innovation and
Regulatory Science 2015; 49:584–592.
[12] Garrett A. Choosing appropriate estimands in clinical trials (Leuchs
et al.): Letter to the editor. Therapeutic Innovation & Regulatory Sci-
ence 2015; 49:601.
[13] Carpenter J, Roger J, Kenward M. Analysis of longitudinal trials with
missing data: a framework for relevant, accessible assumptions,
and inference via multiple imputation. Journal of Biopharmaceutical
Statistics 2013; 23:1352–1371.
[14] Mallinckrodt CH, Roger J, Chuang-Stein C, et al. Recent develop-
ments in the prevention and treatment of missing data. Therapeutic
Innovation and Regulatory Science 2014; 48(1):68–80.
[15] Mallinckrodt CH, Roger J, Chuang-Stein C, et al. Missing data: turn-
ing guidance into action. Statistics in Biopharmaceutical Research
2013; 5(4):369–382.
[16] Permutt T. A taxonomy of estimands for regulatory clinical
trials with discontinuations. Statistics in Medicine 2015a. DOI:
10.1002/sim.6841
[17] Phillips A, Abellan-Andres J, Andersen S, et al. Estimands: discus-
sion points from the PSI estimands and sensitivity expert group.
Pharmaceutical Statistics 2016. DOI: 10.1002/pst.1745
[18] ICH guidelines. Available at: http://www.ich.org/fileadmin/
Public/Web/Site/ICH/Products/Guidelines/Efficacy/E9/Step4/E9/
Guideline.pdf (accessed 19.10.2015).
[19] Buncher C, Ralph and Jia-Yeong Tsay. Statistics in the pharmaceutical
industry (3rd edition). Chapman Hall/CRC Press: Boca Raton, FL USA,
2005.
Pharmaceut. Statist. 2016 Copyright © 2016 John Wiley & Sons, Ltd.
C. H. Mallinckrodt, S. Rathmann and G. Molenberghs
[20] Holubkov R1, Dean JM, Berger J, Anand KJ, Carcillo J, Meert K,
Zimmerman J, Newth C, Harrison R, Willson DF, Nicholson C. Is
“rescue” therapy ethical in randomized controlled trials? Pediatric
Critical Care Medicine 2009; 10(4):431–8.
[21] Henning Z. Paracetamol and the placebo effect in osteoarthritis tri-
als: amissing link? Pain Research and Treatment 2011; 2011:6, Article
ID 696791.
[22] ICH guidelines, Available at: http://www.ich.org/fileadmin/
Public/Web/Site/ICH/Products/Guidelines/Efficacy/E10/Step4/E10/
Guideline.pdf (accessed 21.10.2015).
[23] Verbeke G, Molenberghs G. Linear Mixed models for longitudinal
data. Springer: New York, NY, USA, 2000.
[24] Molenberghs G, Beunckens C, Sotto C, Kenward M.G. Every miss-
ing not at random model has got a missing at random counterpart
with equal fit. Journal of the Royal Statistical Society, Series B. 2008;
70:371–388.
[25] Kim Y. Missing data handling in chronic pain trials. Journal of Bio-
pharmaceutical Statistics 2011; 21(2):311–325.
[26] Kenward MG, Molenberghs G. Last observation carried for-
ward: a crystal ball? Journal of Biopharmaceutical Statistics 2009;
19:872–888.
[27] SAS Institute Inc. SAS/STAT®9.4. User’s guide. SAS Institute Inc: Cary,
NC, 2013.
[28] Ayela B, Lipkovich I, Molenberghs G, Mallinckrodt CH. A multiple
imputation-based approach to sensitivity analyses and effective-
ness assessments in longitudinal clinical trials. Journal of Biophar-
maceutical Statistics 2014; 24(2):211–228.
[29] Goldstein DJ, Lu Y, Detke MJ, Wiltse C, Mallinckrodt C, Demitrack
MA. Duloxetine in the treatment of depression: a double-blind
placebo-controlled comparison with paroxetine. Journal of Clinical
Psychopharmacology 2004; 24:389–399.
[30] Detke MJ, Wiltse CG, Mallinckrodt CH, McNamara RK, Demitrack
MA. Bitter I. Duloxetine in the acute and long-term treatment of
major depressive disorder: a placebo- and paroxetine-controlled
trial. European Neuropsychopharmacology 2004; 14(6):457–470.
[31] Hamilton M. A rating scale for depression. Journal of Neurology,
Neurosurgery & Psychiatry 1960; 23:56–61.
[32] Flemming TR. Addressing missing data in clinical trials. Annals of
Internal Medicine 2011; 154:113–117.
Copyright © 2016 John Wiley & Sons, Ltd. Pharmaceut. Statist. 2016
